147 related articles for article (PubMed ID: 27919216)
1. Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints.
D Arcy N; Gabrielli B
Curr Med Chem; 2017; 24(15):1504-1519. PubMed ID: 27919216
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol acts as a topoisomerase II poison in human glioma cells.
Leone S; Basso E; Polticelli F; Cozzi R
Int J Cancer; 2012 Aug; 131(3):E173-8. PubMed ID: 22095529
[TBL] [Abstract][Full Text] [Related]
3. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Jain CK; Roychoudhury S; Majumder HK
Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
[TBL] [Abstract][Full Text] [Related]
4. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints.
Kaufmann WK
Proc Soc Exp Biol Med; 1998 Mar; 217(3):327-34. PubMed ID: 9492343
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
Ortega JA; Riccardi L; Minniti E; Borgogno M; Arencibia JM; Greco ML; Minarini A; Sissi C; De Vivo M
J Med Chem; 2018 Feb; 61(3):1375-1379. PubMed ID: 29077404
[TBL] [Abstract][Full Text] [Related]
6. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
[TBL] [Abstract][Full Text] [Related]
7. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells.
Sudan S; Rupasinghe HP
Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698
[TBL] [Abstract][Full Text] [Related]
8. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
9. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel catalytic inhibitor of topoisomerase II alpha that engages distinct mechanisms in p53
Lee SF; Hirpara JL; Qu J; Yadav SK; Sachaphibulkij K; Pervaiz S
Cancer Lett; 2022 Feb; 526():284-303. PubMed ID: 34843865
[TBL] [Abstract][Full Text] [Related]
11. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
12. An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quantified by comparative analysis centered on the clinical candidate F14512.
Palermo G; Minniti E; Greco ML; Riccardi L; Simoni E; Convertino M; Marchetti C; Rosini M; Sissi C; Minarini A; De Vivo M
Chem Commun (Camb); 2015 Oct; 51(76):14310-3. PubMed ID: 26234198
[TBL] [Abstract][Full Text] [Related]
13. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
14. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines.
Nakagawa T; Hayashita Y; Maeno K; Masuda A; Sugito N; Osada H; Yanagisawa K; Ebi H; Shimokata K; Takahashi T
Cancer Res; 2004 Jul; 64(14):4826-32. PubMed ID: 15256452
[TBL] [Abstract][Full Text] [Related]
15. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β.
Ortega JA; Arencibia JM; Minniti E; Byl JAW; Franco-Ulloa S; Borgogno M; Genna V; Summa M; Bertozzi SM; Bertorelli R; Armirotti A; Minarini A; Sissi C; Osheroff N; De Vivo M
J Med Chem; 2020 Nov; 63(21):12873-12886. PubMed ID: 33079544
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of the novel DNA topoisomerase II inhibitors: esterification and amination substituted 4'-demethylepipodophyllotoxin derivates exhibiting anti-tumor activity by activating ATM/ATR signaling pathways.
Xiao L; Zhao W; Li HM; Wan DJ; Li DS; Chen T; Tang YJ
Eur J Med Chem; 2014 Jun; 80():267-77. PubMed ID: 24793877
[TBL] [Abstract][Full Text] [Related]
18. Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles.
Plech T; Kaproń B; Paneth A; Wujec M; Czarnomysy R; Bielawska A; Bielawski K; Trotsko N; Kuśmierz E; Paneth P
J Enzyme Inhib Med Chem; 2015 Dec; 30(6):1021-6. PubMed ID: 25792499
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.
McNamara AV; Barclay M; Watson AJ; Jenkins JR
Biochem Pharmacol; 2012 Feb; 83(3):355-67. PubMed ID: 22138446
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the topoisomerase II-dependent decatenation G2 checkpoint and checkpoint kinases in human cells.
Kaufmann WK
Methods Mol Biol; 2009; 582():155-66. PubMed ID: 19763949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
